[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371153-105":59,"doc-detail-371153-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pretreatment-neutrophil-to-lymphocyte-ratio-is-associated-with-immunotherapy-efficacy-in-patients-with-advanced-cancer-a-systematic-review-and-meta-analysis","Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer - a systematic review and meta-analysis","","This systematic review and meta-analysis evaluates whether the pretreatment neutrophil-to-lymphocyte ratio (NLR) predicts outcomes for patients with advanced cancer receiving immunotherapy. Searches across Embase, PubMed, Web of Science, and Cochrane Library identified cohort studies reporting baseline NLR up to November 29, 2024. Using random-effects pooling and risk-of-bias assessment via Egger and GRADE, 129 articles covering 18,780 cases were included. Elevated pretreatment NLR correlated with worse OS and PFS and lower ORR and DCR, though evidence quality was limited by bias and inconsistency.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pretreatment-neutrophil-to-lymphocyte-ratio-is-associated-with-immunotherapy-efficacy-in-patients-with-advanced-cancer-a-systematic-review-and-meta-analysis/371153/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pretreatment-neutrophil-to-lymphocyte-ratio-is-associated-with-immunotherapy-efficacy-in-patients-with-advanced-cancer-a-systematic-review-and-meta-analysis/371153.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study evaluate regarding pretreatment NLR?","Question",{"text":112,"@type":113},"It assesses whether the pretreatment neutrophil-to-lymphocyte ratio predicts prognosis and immunotherapy efficacy in patients with advanced cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and timeframe were used to collect the evidence?",{"text":117,"@type":113},"The review searched Embase, PubMed, Web of Science, and Cochrane Library up to November 29, 2024.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were analyzed in relation to pretreatment NLR?",{"text":121,"@type":113},"Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were evaluated using pooled effect estimates.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371153,1790217430,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPretreatment neutrophil-tolymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis  \nJialin Su1,2, Yuning Li1,2, Shuhua Tan2, Tianli Cheng1, Yongzhong Luo1 & Lemeng Zhang1􀀍  \nThis study aimed to systematically investigate the value of the pre-treatment neutrophil-tolymphocyte ratio (NLR) in prognosticating the outcome of patients with advanced cancer receiving immunotherapy. We searched Embase, PubMed, Web of Science, and Cochrane Library to identify studies about cancer patients with immunotherapy until November 29, 2024. Retrospective or prospective cohort studies with pretreatment NLR data were included. The odds ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the predictive value of NLR in prognosis and immunotherapy efficacy. The random effect model was applied for meta-analysis and the risk of bias was assessed by Egger test and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method. A total of 129 articles involving 18780 cases were finally selected. Most cases were advanced cancers with the median follow-up period ranged 2–48.6 months. The high pretreatment NLR level was associated with the significantly reduced OS (HR (95%CI) = 2.26 (2.03, 2.53)), PFS (HR (95% CI) = 1.83 (1.69, 1.98)), ORR (OR (95%CI) = 0.53 (0.46, 0.61)) and DCR (OR (95% CI) = 0.36 (0.29, 0.43)) in patients with advanced cancer receiving immunotherapy. The quality of  \nevidence was low, attributed to the serious risk of bias and incon¬sistency. An elevated NLR before immunotherapy was significantly associated with poor clinical outcomes in patients with advanced cancer.  \nKeywords Advanced cancer, Neutrophil-to-lymphocyte ratio, Immunotherapy, Meta-analysis  \nAdvanced cancer poses a significant global health threat, with its incidence on rise1. Immunotherapy has revolutionized the landscape of cancer treatment2,3, offering unprecedented survival advantages4. Despite its efficacy, immunotherapy is effective only for select patients, with many individuals failing to respond5. Tumor mutational burden, programmed death ligand-1, tumor-infiltrating lymphocytes, and microsatellite instability are gaining importance in the selection of treatment options6. However, these biomarkers have some limitations, such as being unsuitable for dynamic monitoring, high cost, and inconsistent viability7,8. Thus, the urgent need arises for identifying biomarkers that are readily available at a low cost for routine clinical use without specialized genomic technologies. The neutrophil-to-lymphocyte ratio (NLR), defined as the absolute counts of neutrophils and lymphocytes, has been reported to be a predictive biomarker of mortality in all conditions, including cancers9–12. NLR has been an emerging marker of the association between immune system and diseases13. Considering the interplay among systemic inflammation, immune system, and immunotherapy, NLR may be an attractive biomarker for predicting the efficacy of immunotherapy in cancer patients. Despite some studies14–17 and meta-analyses18–20 have examined the clinical application of NLR for immunotherapy efficacy in patients with advanced cancer, the results are inconsistent. With the development of immunotherapy, and updated clinical data, the performance of the NLR value in prognosticating immunotherapy efficacy deserves further exploration. To obtain objective and comprehensive results, we performed meta-analysis to evaluate the  \n1Thoracic Medicine Department 1, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Tongzipo Rd 283\\#, Yuelu District, Changsha 410013, Hunan Province, People’s Republic of China. 2School of Life and Health Sciences, Hunan University of Science and Technology, Xiangtan 411201, People’s Republic of China. 􀀍 email: [zhanglemeng@hnca","cbCaimiyR76d2AHk","https://ap.wps.com/l/cbCaimiyR76d2AHk","pdf",3995587,17,"English","# Materials and methods\n## Search strategy\n## Literature screening","[{\"question\":\"What does the study evaluate regarding pretreatment NLR?\",\"answer\":\"It assesses whether the pretreatment neutrophil-to-lymphocyte ratio predicts prognosis and immunotherapy efficacy in patients with advanced cancer.\"},{\"question\":\"Which databases and timeframe were used to collect the evidence?\",\"answer\":\"The review searched Embase, PubMed, Web of Science, and Cochrane Library up to November 29, 2024.\"},{\"question\":\"What outcomes were analyzed in relation to pretreatment NLR?\",\"answer\":\"Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were evaluated using pooled effect estimates.\"}]","Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer - a systematic review and meta-analysis | PDF",1790191414,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/982b27ea710ee013143ae0079d7ded51.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ba8f24e55c93bcd9c1603825c2fb278.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e681a02135fe1ca27c5e71f2dc63bcf0.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08b5dfda4081b85f47afd024cff14939.webp",980,1287]